News

Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) or recurrent CTEPH in Wales now have access to Bayer’s therapy Adempas (riociguat) — a soluble guanylate cyclase (sGC) stimulator that works by relaxing blood vessels and increasing the supply of blood to the lungs, which helps reduce the workload of the heart. The All Wales Medicines…

In a new study, researchers have investigated the impact of cancer diagnosis on the prediction of right ventricular dysfunction (RVD) in acute pulmonary embolism (PE) patients using cardiac troponin I (cTnI). The study, entitled “Impact of cancer on the effectiveness of cardiac Troponin I to predict right ventricular…

In a new study entitled “Signaling pathways underlying skeletal muscle wasting in experimental pulmonary arterial hypertension,” researchers investigated the potential mechanisms underlying patients with pulmonary arterial hypertension characteristic skeletal muscle abnormalities. The researchers identified that muscle loss is prompted by accumulation of dysfunctional mitochondrias and ineffective removal of damaged…

A recently published paper in Journal of Pathology and Translational Medicine entitled “Therapeutic Effects of Umbilical Cord Blood Derived Mesenchymal Stem Cell-Conditioned Medium on Pulmonary Arterial Hypertension in Rats” suggests that human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) may be useful…

A recent article suggests prostacyclin therapy, which is used for the treatment of pulmonary arterial hypertension (PAH), may also be useful for treating sarcoidosis-associated pulmonary hypertension (SAPH). PAH refers to high blood pressure of the lungs. The condition can occur as a result of several different diseases, including sarcoidosis; a disease…

Last year, a study entitled “T-Helper 17 Cell Polarization in Pulmonary Arterial Hypertension” published in the Chest journal associated the increased activity of a T-cell-mediated immune process — the T-helper 17 pathway — with Pulmonary Arterial Hypertension (PAH). This research is now being contested by a group of researchers…

In a world where vasodilators rule the landscape of treatments for pulmonary arterial hypertension (PAH), scientific research groups and pharmaceutical companies around the world are working to develop targeted therapeutics that focus on specific cellular pathways that are associated with dysfunction in PAH patients. Within the realm of targeted therapeutics,…

Researchers at the Yale Cardiovascular Research Center have identified a specialized cell type involved in pulmonary hypertension pathogenesis. The research paper, entitled “Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension,” was published in Science Translational Medicine. Pulmonary hypertension (PH) is a life-threatening…

October 13 is World Thrombosis Day, an event that increases global awareness and focuses attention on the often overlooked and misunderstood disease of thrombosis as an urgent and growing health problem. In recognition of World Thrombosis Day and the seriousness and prevalence of venous thromboembolism (VTE), the Montreal,…

Non-invasive techniques to detect pulmonary hypertension in individuals who are at a high risk for developing the disease are in high demand to enable more patients to be diagnosed and treated in the early stages. As the gold standard, right heart catheterization has been the primary mode of detecting an increase…

Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved Letairis® (ambrisentan) with tadalafil for pulmonary arterial hypertension (PAH) to diminish disease progression risk and hospitalization and to improve the ability to exercise — a decision that directly follows recent study results indicating the…

In a recent study titled, “Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension,” published in the New England Journal of Medicine, a global team of researchers demonstrated that treatment combining ambrisentan and tadalafil significantly improves the clinical condition of pulmonary arterial hypertension patients.